



PRESIDENT- CEO UPDATE – MAY 2009

CurePSP's Expanded Vision and Mission

Over the years, **CurePSP** has helped thousands of people with PSP, CBD and related disorders. Our services benefited people who also suffered with multiple system atrophy (MSA) and other rare neurodegenerative diseases. Our Brain Bank at the Mayo Clinic also confirms that a small percentage of those people who had been diagnosed with PSP actually had another very closely related disorder such as CBD or MSA.

In October 2008, a Mission Expansion Study Committee was tasked to explore the benefits and costs of expanding our mission to include some of these related disorders. The reasons for recommending a mission expansion were:

- *To enable CurePSP to serve more patients and families with PSP, CBD and related disorders*
- *To enhance research efforts to include other PSP-like disorders*
- *To expand our constituent base in order to raise more funds for research, outreach, education, operating expenses and advocacy*

After an extensive study of twenty-three related or associated disorders, the Board of **CurePSP** decided to expand the mission to include five additional disorders in both or either our research mission or our outreach & education mission. The five are:

- argyrophilic grain disease (AGD): for both Research and O&E
- lytico-bodig (LyB): for Research
- Guadelupean tauopathy (GT): for Research
- multiple system atrophy (MSA): for Outreach & Education. While MSA is not a tauopathy, it has many features similar to PSP and CBD.
- pallidal degeneration (PaD): for O&E

Our new vision statement is:

Cure and Prevent PSP, CBD and related disorders

Our new mission statement is:

Increase awareness of progressive supranuclear palsy, corticobasal degeneration, and related disorders, fund research toward a cure and prevention, educate healthcare professionals, and provide support, information and hope for persons affected by these disorders and their families.

Because of these additional changes to our mission, **CurePSP** will now be called **CurePSP+** to reflect these changes in services for PSP, CBD and five other related disorders. Our board is also working on a revised logo to reflect these changes in mission.

There will be much more information to come on these changes including a new and improved web site, which should be fully implemented by the beginning of the new fiscal year in July. Much progress has been made and much more must still be done. I thank you for your interest, commitment, and support.

Richard Gordon Zyne, DMin
President-CEO